The effect of tolvaptan in heart failure patients with loop diuretic resistance.

The effect of tolvaptan in heart failure patients with loop diuretic resistance. - The effect of tolvaptan in heart failure patients with loop diuretic resistance.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016655

Enrollment

Registered

2015-02-27

Start date

2014-02-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure

Interventions

administration of tolvaptan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hospitalized heart failure patients with informed consent, and whose urine production is less than 200ml over 2h after intravenous bolus of furosemide.

Exclusion criteria

Exclusion criteria: 1. patients with cardiogenic shock or needs catecholamine or mechanical circulation support 2. intubation 3. obvious bleeding or active gastrointestinal ulceration 4. hemodialysis 5. hyperkalemia (6.0mEq/L) 6. hypernatremia (150mEq/L) 7. hypotension (systolic blood pressure <=85mmHg) or symptomatic hypotension 8. patients who cannot declare thirst or cannot drink water 9. hypersensitivity for Tolvaptan or Mozavaptan 10. expectant mother 11. inappropriate patients judged by the physician in charge

Design outcomes

Primary

Measure	Time frame
Changes in body weight	—

Countries

Japan

Contacts

Public ContactKentaro Jujo

Tokyo Women's Medical University Department of cardiology

juken1123@mac.com03-3353-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026